ArticleThe British journal of ophthalmology2017
Topical 1% 5-fluoruracil as a sole treatment of corneoconjunctival ocular surface squamous neoplasia: long-term study.
Article in The British journal of ophthalmology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 80 citations in OpenAlex.
- Topical 5-fluorouracil 1% versus surgical removal as a primary treatment modality for ocular surface squamous neoplasia: a comparison of recurrences and side effects.BMC ophthalmology · 2025Article
- Update in the Diagnosis and Management of Ocular Surface Squamous Neoplasia (OSSN).Journal of clinical medicine · 2025Review
- Oncological principles in the management of ocular surface squamous neoplasia - A Review.Indian journal of ophthalmology · 2025Review
- Clinical profile and outcomes of ocular surface squamous neoplasia at the Philippine General Hospital: a retrospective study.International journal of ophthalmology · 2025Article
- Topical 5-Fluorouracil 0.5% as primary treatment for Ocular Surface Squamous Neoplasia.European journal of ophthalmology · 2025Article
- Infectious etiologies of conjunctival tumors.Expert review of ophthalmology · 2025Article
- IFNα2b/5-FU inhibits proliferation and cell cycle of squamous carcinoma cell line Cal27.International journal of ophthalmology · 2025Article
- Article
- Efficacy of topical 5-Fluorouracil in the management of ocular surface squamous neoplasia: a study of 101 eyes.International ophthalmology · 2024Article
- Update in ocular surface squamous neoplasia.Revista da Associacao Medica Brasileira (1992) · 2024Review
- Medical treatment for ocular surface squamous neoplasia.Eye (London, England) · 2023Review
- The Management of Ocular Surface Squamous Neoplasia (OSSN).International journal of molecular sciences · 2022Review
- Human papillomavirus-related neoplasia of the ocular adnexa.Acta ophthalmologica · 2022Article
- Topical Chemotherapy for Treating Ocular Surface Squamous Neoplasia with a Combination of Interferon α-2b and 5-Fluorouracil.Ophthalmology and therapy · 2022Article
- Treatment challenges associated with a superiorly located bulbar conjunctival mass-case report and review of the literature.American journal of ophthalmology case reports · 2022Article
- Genomic Alterations in Human Papillomavirus-Positive and -Negative Conjunctival Squamous Cell Carcinomas.Investigative ophthalmology & visual science · 2021Article
- Ocular surface squamous neoplasia: management and outcomes.Eye (London, England) · 2021Review
- Iatrogenic Ocular Surface Diseases Occurring during and/or after Different Treatments for Ocular Tumours.Cancers · 2021Review
- Update on the Management of Ocular Surface Squamous Neoplasia.Current ophthalmology reports · 2021Article
- Single-Fraction Adjuvant Electronic Brachytherapy after Resection of Conjunctival Carcinoma.Cancers · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo report long-term clinical outcome of topical 1% 5-fluoruracil (5-FU) as a sole treatment of ocular surface squamous neoplasia (OSSN).
methods41 patients affected by OSSN were included. Each patient underwent full ophthalmological examination at baseline, with cytological or histological confirmation. Patients were treated by topical chemotherapy with 1% 5-FU four times a day for 4 weeks. One course was defined as 4 weeks of topical chemotherapy. Adjunctive courses were administered after 1 month of chemotherapy-free interval.
resultsMean follow-up was 105±32 months (range 60-171 months). Complete tumour regression was achieved in 34 cases (83%) after a mean of 1.5 courses (range, 1-3 courses). Univariate analysis revealed that complete response was significantly related to tumour thickness <1.5 mm (p=0.005), lack of fornix or tarsal involvement (p=0.015 and p=0.009, respectively) and the absence of multifocality (p=0.002). Histopathological diagnosis (intraepithelial neoplasia vs squamous cell carcinoma, p=0.019) and American Joint Committee on Cancer (AJCC) classification (T1 vs T2 or T3) (p=0.028) were also related to incomplete tumour response. In a multivariate analysis, just tumour thickness >1.5 mm (p=0.045) and multifocality (p=0.023) were correlated with incomplete tumour response. Transient and reversible low-to-mild local side effects were documented in 19 (48%) eyes.
conclusionTopical 5-FU, as a sole therapy, is a long-term safe and effective treatment for patients affected by preinvasive OSSN and for a limited proportion (50%) of invasive OSSN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.